Forty percent of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
NORC at the University of Chicago, together with the West Health Institute, released the results of a survey of American adults concerning their attitudes toward healthcare. They found that “healthcare costs have a significant and enduring impact on financial health.”
The survey was conducted among 1302 adults—providing a sample coverage of approximately 97% of US households—between February 15 and February 19 of this year using the AmeriSpeak Panel.
In the past year:
Other Americans reported going without care in order to save money, 40% of respondents had skipped a medical test or treatment to save on costs, and 32% had skipped filling a prescription (or took less medication than prescribed) because of costs.
Among those who had skipped a test or treatment, 60% said that they were afraid of the cost of a serious illness, while only 47% said that they were afraid of getting a serious illness itself. According to the report’s authors, these fears about the cost of treatment are often based on experience; more respondents who had negative financial impacts from previous healthcare costs (56%) feared paying for care than those who had not had previous experiences with financial hardship from healthcare costs (23%).
“It’s shocking and unacceptable that medical bills strike more fear in the hearts of Americans than serious illness,” said Shelley Lyford, president and CEO of West Health Institute, in a statement. “Americans are paying more for healthcare than they should and getting less than they deserve. Bold action is required to lower the sky-high cost of healthcare. The very health and wealth of our nation and its people are at stake.”
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Aflibercept Legal Drama; PBM, Humira Biosimilars; Denosumab Regulatory Review
October 15th 2024Regeneron appeals legal decision after judge refuses to block an aflibercept biosimilar; Prime Therapeutics, a pharmacy benefit manager (PBM), becomes the latest to offer biosimilars referencing Humira (adalimumab) at a low cost; the FDA and European Medicines Agency accept a denosumab biosimilar candidate for review.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Sandoz Report: A Unified Approach to Overcoming Drug Shortages
October 10th 2024A report from Sandoz emphasizes the need for collaboration among stakeholders to eliminate drug shortages impacting over 90% of hospital systems in the US, recommending policy changes and actions to address the ongoing issue, which has caused treatment delays and increased costs.